Stockreport

FDA clamps partial hold on Phase III trial of BioNTech & OncoC4's NSCLC therapy [Yahoo! Finance]

Xilio Therapeutics, Inc.  (XLO) 
PDF the registrational Phase III PRESERVE-003 trial of BioNTech and OncoC4's gotistobart. The study was placed on partial hold after the therapy showed “varying results be [Read more]